Radiolabeled peptide-receptor ligands in tumor imaging

Expert Opinion on Medical Diagnostics

Volumn 5, Issue 5, 2011, Pages 411-424

  Ruzza, Paolo ^a   Calderan, Andrea ^a  

^a CNR   (Italy)

Author keywords

Cancer; Peptide receptor ligands; Radionuclides

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ALPHA INTERMEDIN; BOMBESIN RECEPTOR; CHOLECYSTOKININ RECEPTOR; CONTRAST MEDIUM; INTEGRIN RECEPTOR; LIGAND; NEUROPEPTIDE Y RECEPTOR; NEUROTENSIN RECEPTOR; PENTETIC ACID; PEPTIDE; RADIOPHARMACEUTICAL AGENT; RECEPTOR; SOMATOSTATIN RECEPTOR; SUBSTANCE P RECEPTOR; TRIENTINE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

BINDING AFFINITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; GENE OVEREXPRESSION; HUMAN; ISOTOPE LABELING; LIGAND BINDING; MOLECULAR IMAGING; RECEPTOR AFFINITY; REVIEW; TUMOR CELL; TUMOR DIAGNOSIS;

EID: 80052051610     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2011.592829     Document Type: Review

References (138)

1. Hoffman JM, Gambhir SS Molecular imaging. The vision and opportunity for radiology in the future. Radiology 2007;244:39-47 (Pubitemid 46981957)
2. Cai WB, Chen XY Nanoplatforms for targeted molecular imaging in living subjects. Small 2007;3:1840-54
3. Kwekkeboom DJ, Kam BL, Van Essen M, et al. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010;5:R53-73
4. Haubner R, Decristoforo C. Radiolabelled RGD peptides and peptidomimetics for tumour targeting. Front Biosci 2009;14:872-86
5. Dorbes S, Mestre-Voegtle B, Coulais Y, et al. Synthesis, characterization and in vitro evaluation of new oxorhenium-and oxotechnetium-CCK4 derivatives as molecular imaging agents for CCK2-receptor targeting. Eur J Med Chem 2010;45:423-9
6. Liu ZF, Yan YJ, Chin FT, et al. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using F-18-labeled PEGylated RGD-Bombesin Heterodimer F-18-FB-PEG(3)-Glu-RGD-BBN. J Med Chem 2009;52:425-32
7. Garcia-Garayoa E, Blauenstein P, Blanc A, et al. A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours. Eur J Nucl Med Mol Imaging 2009;36:37-47
8. Singh P. Role of annexin-II in GI cancers: Interaction with gastrins/progastrins. Cancer Lett 2007;252:19-35 (Pubitemid 46759505)
9. Khan IU, Zwanziger D, Bohme I, et al. Breast-cancer diagnosis by Neuropeptide Y Analogues: From synthesis to clinical application. Angew Chem Int Ed Engl 2010;49:1155-8
10. Quinn T, Zhang X, Miao Y Targeted melanoma imaging and therapy with radiolabeled alpha-melanocyte stimulating hormone peptide analogues. G Ital Dermatol Venereol 2010;145:245-58
11. Weiner R, Thakur M. In: Chinol M, Paganelli G, editors, Radionuclide peptide cancer therapy, Taylor & Francis. New York; 2006:41-85
12. Lee S, Xie J, Chen XY. Peptide-based probes for targeted molecular imaging. Biochemistry 2010;49:1364-76
13. Chen K, Conti PS. Target-specific delivery of peptide-based probes for PET imaging. Adv Drug Deliv Rev 2010;62:1005-22
14. Kuil J, Velders AH, van Leeuwen FWB. Multimodal tumor-targeting peptides functionalized with both a radio-and a fluorescent label. Bioconjugate Chem 2010;21:1709-19
15. Bellmann-Sickert K, Beck-Sickinger AG. Peptide drugs to target G protein-coupled receptors. Trends Pharmacol Sci 2010;31:434-41
16. Dijkgraaf I, Boerman OC. Molecular imaging of angiogenesis with SPECT. Eur J Nucl Med Mol Imaging 2010;37:S104-13
17. Sancho V, Di Florio A, Moody TW, et al. Bombesin receptor-mediated imaging and cytotoxicity: review and current status. Curr Drug Deliv 2011;8:79-134
18. Schottelius M, Wester HJ. Molecular imaging targeting peptide receptors. Methods 2009;48:161-77
19. Reubi JC, Landolt AM. High density of somatostatin receptors in pituitary tumors from acromegalic patients. J Clin Endocrinol Metab 1984;59:1148-51 (Pubitemid 15223351)
20. Pool SE, Krenning EP, Koning GA, et al. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med 2010;40:209-18
21. Khan IU, Beck-Sickinger AG. Targeted tumor diagnosis and therapy with peptide hormones as radiopharmaceuticals. Anticancer Agents Med Chem 2008;8:186-99
22. Bolzati C, Refosco F, Marchiani A, et al. Tc-99m-radiolabelled peptides for tumour imaging: present and future. Curr Med Chem 2010;17:2656-83
23. Ferro-Flores G, Ramirez FM, Melendez-Alafort L, Santos-Cuevas CL. Peptides for in vivo target-specific cancer imaging. Mini Rev Med Chem 2010;10:87-97
24. Lee S, Xie J, Chen XY. Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev 2010;110:3087-111
25. Available from: http://clinicaltrials.gov
26. Available from: https://scifinder.cas.org
27. Gentilucci L, De Marco R, Cerisoli L. Chemical modifications designed to improve peptide stability: Incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr Pharm Des 2010;16:3185-203
28. Eifler-Lima VL, Graebin CS, Uchoa FD, et al. Highlights in the solid-phase organic synthesis of natural products and analogues. J Braz Chem Soc 2010;21:1401-23
29. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228-47 (Pubitemid 43817847)
30. Meisetschlager G, Poethko T, Stahl A, et al. Gluc-Lys(F-18 FP)-TOCA PET in patients with SSTR-positive tumors: Biodistribution and diagnostic evaluation compared with In-111 DTPA-octreotide. J Nucl Med 2006;47:566-73 (Pubitemid 46768456)
31. Schottelius M, Poethko T, Herz M, et al. First F-18-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res 2004;10:3593-606 (Pubitemid 38697592)
32. Aloj L, Morelli G. Design, synthesis and preclinical evaluation of radiolabeled peptides for diagnosis and therapy. Curr Pharm Des 2004;10:3009-31 (Pubitemid 39214008)
33. Reubi JC, Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2002;29:855-62 (Pubitemid 34671290)
34. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30:781-93 (Pubitemid 36612963)
35. Zhang HW, Chen JH, Waldherr C, et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 2004;64:6707-15 (Pubitemid 39302601)
36. Garcia-Garayoa E, Schibli R, Schubiger PA. Peptides radiolabeled with Re-186/188 and Tc-99 m as potential diagnostic and therapeutic agents. Nucl Sci Tech 2007;18:88-100
37. Okarvi SM. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev 2004;24:357-97 (Pubitemid 38495786)
38. Dijkgraaf I, Boerman OC, Oyen WJ, et al. Development and application of peptide-based radiopharmaceuticals. Anticancer Agents Med Chem 2007;7:543-51
39. Ginj M, Zhang HW, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 2006;103:16436-41 (Pubitemid 44715214)
40. Cescato R, Maina T, Nock B, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008;49:318-26 (Pubitemid 351225672)
41. Dijkgraaf I, Anton M, Koglin N, et al. Targeting metastatic processes by nuclear and optical probes. Interdisciplinary molecular imaging meeting of German X-ray society (DRG), the German Society of Nuclear Medicine (DGN), the German Society of Biomedical Physics (DGBMT), the German Society of Medical Physics (DGMP) and the German Network of Molecular Imaging; 2007, Kiel, Germany
42. Liu ZF, Yan YJ, Chin FT, et al. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using F-18-labeled PEGylated RGD-Bombesin Heterodimer F-18-FB-PEG(3)-Glu-RGD-BBN. J Med Chem 2009;52:425-32
43. Liu ZF, Wang F. Dual-targeted molecular probes for cancer imaging. Curr Pharm Biotechnol 2010;11:610-19
44. Liu ZF, Niu G, Wang F, et al. Ga-68-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging 2009;36:1483-94
45. Josan JS, Vagner J, Handl HL, et al. Solid-phase synthesis of heterobivalent ligands targeted to melanocortin and cholecystokinin receptors. Int J Pept Res Ther 2008;14:293-300
46. Ruzza P, Marchiani A, Antolini N, et al. Peptide-receptor ligands and multivalent approach. Anticancer Agents Med Chem 2011; submitted
47. Reubi JC. In: Chinol M, Paganelli G, editors, Radionuclide peptide cancer therapy Taylor & Francis. New York; 2006: 31-9
48. Dijkgraaf I, Kruijtzer JAW, Liu S, et al. Improved targeting of the alpha(v)beta(3) integrin by multimerization of RGD peptides. Eur J Nucl Med Mol Imaging 2007;34:267-73 (Pubitemid 46147510)
49. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin alpha(v)beta(3) targeted radiotracers for tumor imaging. Mol Pharm 2006;3:472-87 (Pubitemid 44639125)
50. Liu ZF, Jia B, Shi JY, et al. Tumor uptake of the RGD dimeric probe Tc-99m-G(3)-2P(4)-RGD2 is correlated with integrin alpha(v)beta(3) expressed on both tumor cells and neovasculature. Bioconjugate Chem 2010;21:548-55
51. Jin ZH, Furukawa T, Waki A, et al. Effect of multimerization of a linear Arg-Gly-Asp peptide on integrin binding affinity and specificity. Biol Pharm Bull 2010;33:370-8
52. Mammen M, Choi SK, Whitesides GM. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed Engl 1998;37:2755-94
53. Vagner J, Xu LP, Handl HL, et al. Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors. Angew Chem Int Ed Engl 2008;47:1685-8
54. Liu ZF, Li ZB, Cao QZ, et al. Small-animal PET of tumors with (64Cu)-labeled RGD-bombesin heterodimer. J Nucl Med 2009;50:1168-77
55. Liu ZF, Niu G, Wang F, et al. Ga-68-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging 2009;36:1483-94
56. Liu ZF, Yan YJ, Chin FT, et al. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using F-18-labeled PEGylated RGD-Bombesin Heterodimer F-18-FB-PEG(3)-Glu-RGD-BBN. J Med Chem 2009;52:425-32
57. Yang JQ, Guo HX, Gallazzi F, et al. Evaluation of a novel Arg-Gly-Asp-Conjugated alpha-melanocyte stimulating hormone hybrid peptide for potential melanoma therapy. Bioconjugate Chem 2009;20:1634-42
58. Yang J, Guo H, Miao Y. Technetium-99 m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptides for human melanoma imaging. Nucl Med Biol 2010;37:873-83
59. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with In-111-DTPA-D-Phe (1)-and I-123-Tyr(3)-Octreotide-the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31 (Pubitemid 23284773)
60. Bakker WH, Albert R, Bruns C, et al. In-111-DTPA-D-Phe1-Octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors-Synthesis, radiolabeling and in vitro validation. Life Sci 1991;49:1583-91
61. Froidevaux S, Heppeler A, Eberle AN, et al. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1, 4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. Endocrinology 2000;141:3304-12 (Pubitemid 32269019)
62. Eberle AN, Mild G, Froidevaux S. Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: applications to somatostatin receptor-expressing tumors. J Recept Signal Transduct Res 2004;24:319-455 (Pubitemid 40053797)
63. Zamora PO, Gulhke S, Bender H, et al. Experimental radiotherapy of receptor-positive human prostate adenocarcinoma with Re-188-RC-160, a directly-radiolabeled somatostatin analogue. Int J Cancer 1996;65:214-20
64. Thakur ML. Radiolabeled peptides-Now and the future. Nucl Med Commun 1995;16:724-32
65. Weiner RE, Thakur ML. Radiolabeled peptides in diagnosis and therapy. Semin Nucl Med 2001;31:296-311 (Pubitemid 33027508)
66. Thorpe SR, Baynes JW, Chroneos ZC. The design and application of residualizing labels for studies of protein catabolism. FASEB J 1993;7:399-405 (Pubitemid 23108553)
67. Ali SA, Warren SD, Richter KY, et al. Improving the tumor retention of radioiodinated antibody: arylcarbohydrate adducts. Cancer Res 1990;50:783-8
68. Govindan SV, Mattes MJ, Stein R, et al. Labeling of monoclonal antibodies with DTPA-appended radioiodinated peptides containing D-amino acids. Bioconjugate Chem 1999;10:231-40 (Pubitemid 29147726)
69. Reist CJ, Garg PK, Alston KL, et al. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res 1996;56:4970-7 (Pubitemid 26374437)
70. Vaidyanathan G, AffleckD J, Bigner DD, Zalutsky MR. Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate. Nucl Med Biol 2002;29:1-11 (Pubitemid 34088158)
71. Foulon CF, Reist CJ, Bigner DD, Zalutsky MR. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. Cancer Res 2000;60:4453-60 (Pubitemid 32103625)
72. Bolton AM, Hunter RM. The labeling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Biochem J 1973;133:529-38
73. Khawli LA, Kassis AI. Synthesis of 125I labeled N-succinimidyl p-iodobenzoate for use in radiolabelling antibodies. Nucl Med Biol 1989;16:727-33 (Pubitemid 19269409)
74. Zalutsky MR, Narula AS. A method for radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine. Appl Radiat Isot 1987;38:1051-5 (Pubitemid 18081682)
75. Garg PK, Zalutsky MR. N-succinimidyl 5-(trialkylstannyl)-3- pyridinecarboxylates: a new class of reagents for protein radioiodination. Bioconjugate Chem 1991;2:50-6
76. Haubner R, Decristoforo C. Radiolabelled RGD peptides and peptidomimetics for tumour targeting. Front Biosci 2009;14:872-86
77. Wangler C, Schirrmacher R, Bartenstein P, et al. Click-chemistry reactions in radiopharmaceutical chemistry: fast & easy introduction of radiolabels into biomolecules for in vivo imaging. Curr Med Chem 2010;17:1092-116
78. Wester HJ, Hamacher K, Stocklin G. A comparative study of N.C.A. fluorine-18 labeling of proteins via acylation and photochemical conjugation. Nucl Med Biol 1996;23:365-72 (Pubitemid 26164971)
79. Fredriksson A, Johnstrom P, Stone-Elander S, et al. Labeling of human C-peptide by conjugation with N-succinimidyl-4-[18F]fluorobenzoate. J Label Compounds Radiopharm 2001;44:509-19 (Pubitemid 32621692)
80. McBride WJ, Sharkey RM, Karacay H, et al. A novel method of F-18 radiolabeling for PET. J Nucl Med 2009;50:991-8
81. Arano Y, Akizawa H, Uezono T, et al. Conventional and high-yield synthesis of DTPA-conjugated peptides: application of a monoreactive DTPA to DTPA-D-Phe(1)-octreotide synthesis. Bioconjugate Chem 1997;8:442-6 (Pubitemid 27236511)
82. Froidevaux S, Heppeler A, Eberle AN, et al. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1, 4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. Endocrinology 2000;141:3304-12 (Pubitemid 32269019)
83. Meares CF, Moi MK, Diril H, et al. Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer Suppl 1990;10:21-6 (Pubitemid 20226475)
84. Heppeler A, Froidevaux S, Macke HR, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Europ J 1999;5:1974-81 (Pubitemid 129502685)
85. Eisenwiener KP, Prata MIM, Buschmann I, et al. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with Ga-67/68 and In-111 for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjugate Chem 2002;13:530-41 (Pubitemid 34535940)
86. Cole WC, Denardo SJ, Meares CF, et al. Serum stability of Cu-67 Chelates-Comparison with In-111 and Co-57. Nucl Med Biol 1986;13:363-8
87. Bass LA, Wang M, Welch MJ, et al. In vivo transchelation of copper-64 from TETA-Octreotide to superoxide dismutase in rat liver. Bioconjugate Chem 2000;11:527-32 (Pubitemid 30597722)
88. Boswell CA, Sun X, Niu W, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem 2004;47:1465-74 (Pubitemid 38327472)
89. Line BR, Mitra A, Nan A, et al. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. J Nucl Med 2005;46:1552-60 (Pubitemid 46173267)
90. Thakur ML. J. Label. Compd Radiopharm 1993;32:365
91. Rey AM. Radiometal complexes in molecular imaging and therapy. Curr Med Chem 2010;17:3673-83
92. Bartholoma MD, Louie AS, Valliant JF, et al. Technetium and gallium derived radiopharmaceuticals: comparing and contrasting the chemistry of two important radiometals for the molecular imaging era. Chem Rev 2010;110:2903-20
93. Alberto R. The chemistry of technetium-water complexes within, the manganese triad: challenges and perspectives. Eur J Inorg Chem 2009:21-31
94. Garcia R, Paulo A, Santos I. Rhenium and technetium complexes with anionic or neutral scorpionates: an overview of their relevance in biomedical applications. Inorg Chim Acta 2009;362:4315-27
95. Guhlke S, Schaffland A, Zamora PO, et al. 188Re-and 99mTc-MAG3 as prosthetic groups for labeling amines and peptides: approaches with pre-and post-conjugate labeling. Nucl Med Biol 1998;25:621-31 (Pubitemid 28442727)
96. Van Domselaar GH, Okarvi SM, Fanta M, et al. Synthesis and 99 mTc-labelling of bz-MAG3-triprolinyl-peptides, their radiochemical evaluation and in vitro receptor-binding. J Label Compd Radiopharm 2000;43:1193-204
97. Chen JQ, Giblin MF, Wang NN, et al. In vivo evaluation of Tc-99m/Re-188-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting. Nucl Med Biol 1999;26:687-93 (Pubitemid 29424760)
98. Decristoforo C, Mather SJ, Cholewinski W, et al. Tc-99m-EDDA/HYNIC-TOC: a new Tc-99-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with In-111-labelled octreotide derivatives. Eur J Nucl Med 2000;27:1318-25
99. Bangard M, Behe M, Guhlke S, et al. Detection of somatostatin receptor-positive tumours using the new Tc-99m-tricine-HYNIC-D-Phe(1)-Tyr (3)-octreotide: first results in patients and comparison with In-111-DTPA-D-Phe (1)-octreotide. Eur J Nucl Med 2000;27:628-37 (Pubitemid 30408763)
100. Lin KS, Luu AN, Baidoo KE, et al. In vivo evaluation of a promising 99mTc-labeled bombesin analog for breast cancer imaging. In; Nicolini M, Mazzi U, editors. Technetium, rhenium, and other metals in chemistry and nuclear medicine 6. Padova: SG Editoriali; 2002. pp. 363-7
101. Verbeke K, Verbeke A, Vanbilloen H, et al. Preparation and preliminary evaluation of 99mTc-EC-For-MLFK. Nucl Med Biol 2002;29:585-92
102. Maina T, Nock B, Nikolopoulou A, et al. Tc-99m demotate, a new Tc-99m-based Tyr(3) octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur J Nucl Med Mol Imaging 2002;29:742-53
103. Biondi B, Bolzati C, Carta D, et al. The Tc(N)PNP metal fragment labeled peptide for MC1 receptors imaging: preliminary studies. J Pept Sci 2010;16:182
104. Abrams MJ, Juweid M, tenKate CI, et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotimamide derivative for imaging focal sites of infection in rats. J Nucl Med 1990;31:2022-8
105. de Jong M, Breeman WAP, Kwekkeboom DJ, et al. Tumor imaging and therapy using radiolabeled somatostatin analogues. Accounts Chem Res 2009;42:873-80
106. Maina T, Nock BA, Zhang HW, et al. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. J Nucl Med 2005;46:823-30
107. Ten Bokum AMC, Rosmalen JGM, Hofland LJ, et al. Tissue distribution of octreotide binding receptors in normal mice and strains prone to autoimmunity. Nucl Med Commun 2002;23:1009-17 (Pubitemid 35178303)
108. Melis M, Krenning EP, Bernard BF, et al. Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: species and gender differences. Nucl Med Biol 2007;34:633-41 (Pubitemid 47248283)
109. Krenning EP, Breeman WAP, Kooij PPM, et al. Localization of endocrine-related tumors with radioiodinated analog of somatostatin. Lancet 1989;1:242-4
110. Stahl A, Meisetschlager G, Schottelius M, et al. I-123 Mtr-TOCA, a radioiodinated and carbohydrated analogue of octreotide: scintigraphic comparison with In-111 octreotide. Eur J Nucl Med Mol Imaging 2006;33:45-52 (Pubitemid 41785308)
111. Smith-Jones PM, Bischof C, Leimer M, et al. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999;140:5136-48
112. Pearson DA, Lister-James J, McBride WJ, et al. Somatostatin receptor-binding peptides labeled with technetium-99m: chemistry and initial biological studies. J Med Chem 1996;39:1361-71 (Pubitemid 26112701)
113. Maina T, Nock B, Nikolopoulou A, et al. Tc-99m demotate, a new Tc-99m-based Tyr(3) octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur J Nucl Med Mol Imaging 2002;29:742-53
114. Decristoforo C, Melendez-Alafort L, Sosabowski JK, et al. Tc-99m-HYNIC-Tyr(3)-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with In-111-octreotide. J Nucl Med 2000;41:1114-19 (Pubitemid 30396667)
115. Storch D, Behe M, Walter MA, et al. Evaluation of Tc-99m/EDDA/HYNIC0 octreotide derivatives compared with In-111-DOTA(0),Tyr(3), Thr(8) octreotide and In-111-DTPA(0) octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med 2005;46:1561-9 (Pubitemid 46173268)
116. Helisch A, Forster GJ, Reber H, et al. Pre-therapeutic dosimetry and biodistribution of Y-86-DOTA-Phe(1)-Tyr(3)-octreotide versus In-111-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31:1386-92 (Pubitemid 39361934)
117. Froidevaux S, Eberle AN, Christe M, et al. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer 2002;98:930-7 (Pubitemid 34286693)
118. Kayani I, Bomanji JB, Groves A, et al. Functional Imaging of neuroendocrine tumors with combined PET/CT using Ga-68-DOTATATE (Dota-DPhe(1),Tyr (3)-octreotate) and F-18-FDG. Cancer 2008;112:2447-55
119. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338-47 (Pubitemid 37247950)
120. Anderson CJ, Pajeau TS, Edwards WB, et al. In-vitro and in-vivo evaluation of copper-64-octreotide conjugates. J Nucl Med 1995;36:2315-25
121. Wester HJ, Schottelius M, Scheidhauer K, et al. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel F-18-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging 2003;30:117-22 (Pubitemid 36692901)
122. Varvarigou AD, Scopinaro F, Leondiadis L, et al. Synthesis, chemical, radiochemical and radiobiological evaluation of a new Tc-99m-labelled bombesin-like peptide. Cancer Biother Radiopharm 2002;17:317-26 (Pubitemid 34765054)
123. Van de Wiele C, Dumont F, Vanden Broecke R, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 2000;27:1694-9
124. Ferro-Flores G, de Murphy CA, Rodriguez-Cortes J, et al. Preparation and evaluation of Tc-99m-EDDA/HYNIC-Lys(3)-bombesin for imaging gastrin-releasing peptide receptor-positive tumours. Nucl Med Commun 2006;27:371-6 (Pubitemid 44315047)
125. Schuhmacher J, Zhang HW, Doll J, et al. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a Ga-68-labeled bombesin(6-14) analog. J Nucl Med 2005;46:691-9 (Pubitemid 41721868)
126. Raderer M, Kurtaran A, Yang Q, et al. Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer. J Nucl Med 1998;39:1570-5 (Pubitemid 28459889)
127. Pallela VR, Thakur ML, Chakder S, et al. Tc-99m-labeled vasoactive intestinal peptide receptor agonist: functional studies. J Nucl Med 1999;40:352-60 (Pubitemid 29077101)
128. Buchegger F, Bonvin F, Kosinski M, et al. Radiolabeled neurotensin analog, Tc-99m-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J Nucl Med 2003;44:1649-54 (Pubitemid 39663339)
129. Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides, tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001;42:326-36 (Pubitemid 32150525)
130. Glaser M, Morrison M, Solbakken M, et al. Radiosynthesis and biodistribution of cyclic RGD peptides conjugated with novel F-18 fluorinated aldehyde-containing prosthetic groups. Bioconjugate Chem 2008;19:951-7 (Pubitemid 351614549)
131. Kolb HC, Walsh JC, Liang Q, et al. 18F-RGD-K5: a cyclic triazole-bearing RGD peptide for imaging integrin alphavbeta3 expression in vivo. J Nucl Med 2009;50(Suppl 2):86
132. Behr TM, Jenner N, Radetzky S, et al. Targeting of cholecystokinin-B/ gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 1998;25:424-30 (Pubitemid 28211607)
133. de Jong M, Bakker WH, Bernard BF, et al. Preclinical and initial clinical evaluation of In-111-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 1999;40:2081-7 (Pubitemid 30022025)
134. Behe M, Becker W, Gotthardt M, et al. Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur J Nucl Med Mol Imaging 2003;30:1140-6 (Pubitemid 36988226)
135. Nock BA, Maina T, Behe M, et al. CCK-2/gastrin receptor-targeted tumor imaging with Tc-99m-labeled minigastrin analogs. J Nucl Med 2005;46:1727-36 (Pubitemid 46211597)
136. Bard DR, Wraight EP, Knight CG. BisMSH-DTPA-a potential imaging agent for malignant-melanoma. Ann N Y Acad Sci 1993;680:451-3 (Pubitemid 23201036)
137. Wild D, Behe M, Wicki A, et al. Lys(40) (Ahx-DTPA-In-111) NH2 exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 2006;47:2025-33 (Pubitemid 47558899)
138. Wild D, Christ E, Gloor B, et al. Glucagon-like Peptide 1 (GLP-1) receptor scans localize hardly detectable insulinomas. Eur J Nucl Med Mol Imaging 2008;35(Suppl 2):S188